Synchronous BRCA2 positive ovarian carcinoma with ALK positive NSCLC: Double troubleNSCLCALKBRCA2PARPiMetachronous and synchronous malignancyLung cancer being a molecularly distinct entity in the female population, multiple primary tumors including the genital and urinary tract malignancies with lung carcinoma...
这种作用可以增加免疫检查点受体(如PD-L1)在肿瘤细胞上的表达,从而增加对检查点抑制剂反应的倾向。 总而言之,该病例显示了奥拉帕利和帕博利珠单抗联合治疗晚期 BRCA2突变伴随PD-L1 阳性的胆管癌患者,作为铂类药物化疗后的二线治疗,有显著临床活性。该疗法耐受性良好,但有必要密切筛查与免疫相关的不良事件,尤其是在敏...
[11] Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer:a report from the Australian Ovarian Cancer Study Group [ J]...
用途范围 Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白。 包装规格 0.5kg 来源 原核表达 片段与标签 Lys2308~His2537 with N-terminal His Tag 性状 冻干粉 宿主 E.coli 可售卖地 北京;天津;河北;山西;内蒙古;辽宁;吉林;黑龙江;上海;江苏;浙江;安徽;福建;...
[28] Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients[J]. Breast Cancer Res Treat, 2014, 147(2):401-405. doi: 10.1007/s10549-01...
Clinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsMutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. Early age at onset is generally considered an indicator of genetic susceptibility to breast cancer. We determined ...
Applications: Positive Control; Immunogen; SDS-PAGE; WB. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 9.7 Predicted Molecular Mass: 29.9kDa Accurate Molecular Mass: 32kDa as determined by SDS-PAGE reducing conditions. ...
应用Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白 序列 用法 Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex. 储存 避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
in index Fanconi case at age 10 (ii) Couch assay of 0.987 (all positive controls were p>0.99) (iii) BRCA2 ubiquitination function intermediate (iii) lack of family history in large pedigree for UK Fanconi case.但是没有具体的文献的引用证据。
Case Report: Complete Clinical Response of a Young Patient with a BRCA 2 Positive Metastatic Breast Cancer DOI: 10.4236/abcr.2013.23010, PP. 56-59 Grazia Artioli, Giuseppe Azzarello, Fabrizio Meggiolaro, Jacopo Wabersich, Lucia Borgato, Mario Bari Keywords: BRCA 2, Breast Cancer, DNA, Cisplati...